Bausch & Lomb licenses Segra compound from Schering

By Elaine Rigoli

Tampa, Fla., Sept. 18 - Bausch & Lomb has obtained an exclusive worldwide license from Schering AG to develop and market a selective glucocorticoid receptor agonist (Segra) for the non-systemic treatment of eye disorders.

Under the agreement, the Rochester, N.Y., eye-health company is responsible for development of the Segra compound for non-systemic use in ophthalmology.

Bausch & Lomb will make upfront and milestone payments based on the development and registration progress, and pay ongoing royalties based on product sales.

Further details of the agreement were not disclosed.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.